ELME vs RNA
ELME: Elme Communities is currently undergoing a formal plan of sale and liquidation to distribute remaining asset value to shareholders. RNA: Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in the heart.
Side-by-side fundamentals
| Metric | ELME | RNA | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $1.63 | $12.11 | |
| Market cap as of 2026-08-08 | $145M | $207M | |
| Net margin as of 2026-08-08 | -54.6% | -172.9% | ELME higher |
| Gross margin as of 2026-08-08 | +59.3% | n/a | |
| Operating margin as of 2026-08-08 | -39.2% | -174.9% | ELME higher |
| ROE as of 2026-08-08 | -13.2% | -40.3% | ELME higher |
| ROA as of 2026-08-08 | -7.5% | -592.6% | ELME higher |
| Debt / equity as of 2026-08-08 | 1.50 | 0.00 | RNA lower |
| Revenue growth (YoY) as of 2026-08-08 | +3.1% | +22.0% | RNA higher |
| Revenue CAGR (3y) SEC XBRL | +12.7% | n/a | |
| Dividend yield as of 2026-08-08 | +5.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-08 | 0.82 | 1.05 | |
| 1-year return as of 2026-08-06 close | -90.0% | -74.9% | RNA higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.